Critical Reviews in Oncology / Hematology
Volume 79, Issue 2 , Pages 91-102 , August 2011

Radiotherapy for invasive breast cancer: Guidelines for clinical practice from the French expert review board of Nice/Saint-Paul de Vence

  • Y. Belkacémi

      Affiliations

    • AP-HP, CHU Henri Mondor, Créteil, Université de Paris XII, France
    • Association of Radiotherapy and Oncology of the Mediterranean arEa (AROME; www.aromecancer.org).
    • Corresponding Author InformationCorresponding author at: Service d’Oncologie-Radiothérapie, Hôpital Henri Mondor, 51 av du Maréchal De-Lattre-de Tassigny, 94000 Créteil Cedex, France. Tel.: +33 1 49 81 45 22; fax: +33 1 49 81 25 89.
    • ,
  • A. Fourquet

      Affiliations

    • Institut Curie, Paris, France
    • Association of Radiotherapy and Oncology of the Mediterranean arEa (AROME; www.aromecancer.org).
    • ,
  • B. Cutuli

      Affiliations

    • Clinique de Courlancy, Reims, France
    • Association of Radiotherapy and Oncology of the Mediterranean arEa (AROME; www.aromecancer.org).
    • ,
  • C. Bourgier

      Affiliations

    • Institut Gustave Roussy, Villejuif, France
    • Association of Radiotherapy and Oncology of the Mediterranean arEa (AROME; www.aromecancer.org).
    • ,
  • M. Hery

      Affiliations

    • Centre Hospitalier Princesse Grace. Monaco, France
    • Association of Radiotherapy and Oncology of the Mediterranean arEa (AROME; www.aromecancer.org).
    • ,
  • G. Ganem

      Affiliations

    • Centre Jean Bernard, Le Mans, France
    • Association of Radiotherapy and Oncology of the Mediterranean arEa (AROME; www.aromecancer.org).
    • ,
  • H. Marsiglia

      Affiliations

    • Institut Gustave Roussy, Villejuif, France
    • University of Florence, Italy
    • Association of Radiotherapy and Oncology of the Mediterranean arEa (AROME; www.aromecancer.org).
    • ,
  • M. Namer

      Affiliations

    • Centre Azuréen de Cancérologie, Mougins, France
    • Association of Radiotherapy and Oncology of the Mediterranean arEa (AROME; www.aromecancer.org).
    • ,
  • J. Gligorov

      Affiliations

    • AP-HP, Hôpital Tenon, Cancer-Est, Paris, France
    • Association of Radiotherapy and Oncology of the Mediterranean arEa (AROME; www.aromecancer.org).
    • ,
  • D. Azria

      Affiliations

    • CRLC Val d’Aurelle, Université Montpellier I, Montpellier, France
    • Association of Radiotherapy and Oncology of the Mediterranean arEa (AROME; www.aromecancer.org).

,Accepted 10 June 2010.

References 

  1. Belot A, Grosclaude P, Bossard N, et al. Cancer incidence and mortality in France over the period 1980–2005. Rev Epidemiol Sante Publique. 2008;56:159–175
  2. Gligorov J, Krakowski I, Luporsi E, Namer M. Recommandations pour la Pratique Clinique: Nice–Saint-Paul-de-Vence 2009. «cancers du sein». Oncologie. 2009;11:495–610
  3. Bellon JR, Come SE, Gelman RS, et al. Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: updated results of a prospective randomized trial. J Clin Oncol. 2005;23:1934–1940
  4. EBCTCG . Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005;366:2087–2106
  5. Whelan T, Pignol JP, Levine MN, et al. Long term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010;362:513–520
  6. Yarnold J, Ashton A, Bliss J, et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial. Radiother Oncol. 2005;75:9–17
  7. START Trialists’ Group , Bentzen SM, Agrawal RK, Aird EG, et al. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet. 2008;371:1098–1107
  8. Romestaing P, Lehingue Y, Carrie C, et al. Role of a 10-Gy boost in the conservative treatment of early breast cancer: results of a randomized clinical trial in Lyon, France. J Clin Oncol. 1997;15:963–968
  9. Romestaing P, Belot A, Hennequin C, et al. Ten-year results of a randomized trial of internal mammary chain irradiation after mastectomy. Int J Radiat Oncol Biol Phys. 2009;75(Suppl. 3):S1;[Abstract 1]
  10. Bartelink H, Horiot JC, Poortmans P, et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med. 2001;345:1378–1387
  11. Bartelink H, Horiot JC, Poortmans PM, et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol. 2007;25:3259–3265
  12. Polgar C, Fodor J, Orosz Z, et al. Electron and high-dose-rate brachytherapy boost in the conservative treatment of stage I–II breast cancer first results of the randomized Budapest boost trial. Strahlenther Onkol. 2002;178:615–623
  13. Overgaard M, Hensen PS, Overgaard J, et al. Post operative radiotherapy in high-risk premenopausal women with breast canecr who receive adjuvant chemotherapy: Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med. 1997;337:949–955
  14. Overgaard M, Hensen PS, Overgaard J, et al. Post operative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomized Trial. Lancet. 1999;353:1641–1648
  15. Ragaz J, Olivotto IA, Spinelli JJ, et al. Locoregional radiation therapy in patients with high risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst. 2005;97:116–126
  16. Nielsen HM, Overgaard M, Grau C, et al. Study of failure pattern among high-risk breast cancer patients with or witout postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danich Breast Cancer Cooperative Group DBCG 82 b and c randomized studies. J Clin Oncol. 2006;24:2268–2275
  17. Wallgren A, Bernier J, Gelbre RD, et al. Timing of radiotherapy and chemotherapy following breast-conservative surgery for patients with node-positive breast cancer. Int J Radiat Oncol Biol Phys. 1996;35:649–659
  18. Jagsi R, Raad RA, Goldberg S, et al. Locoregional recurrence rates and prognostic factors for failure in node-negative patients treated with mastectomy: implications for postmastectomy radiation. Int J Radiat Oncol Biol Phys. 2005;62:1035–1039
  19. Veronesi U, Cascinelli N, Bufalino R, et al. Risk of internal mammary lymph node metastases and its relevance on prognosis of breast cancer patients. Ann Surg. 1983;198:681–684
  20. Pierce LJ, Hutchins LF, Green SR, et al. Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer. J Clin Oncol. 2005;23:24–29
  21. Ahn P, Vu HT, Lanin D, et al. Sequence of radiotherapy with tamoxifen in conservatively managed breast cancer does not affect local relapse rates. J Clin Oncol. 2005;23:17–23
  22. Harris ER, Christensen VJ, Hwang WT, et al. Impact of concurrent versus sequential tamoxifen with radiation therapy in early-stage breast cancer patients undergoing breast conservation treatment. J Clin Oncol. 2005;23:11–16
  23. Azria D, Belkacemi Y, Romieu G, et al. Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for early-stage breast cancer (CO-HO-RT): a phase 2 randomised trial. Lancet Oncol. 2010;11:258–265
  24. Arcangeli G, Pinnaro P, Rambone R, et al. A phase III randomized study on the sequence of radiotherapy and chemotherapy in the conservative management of early-stage breast cancer. Int J Radiat Oncol Biol Phys. 2006;64:161–167
  25. Rouëssé J, De la Lande B, Bertheault-Cvitkovic F, et al. A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: final results. Int J Radiat Oncol Biol Phys. 2006;64:1072–1080
  26. Toledano A, Azria D, Garaud P, et al. Concurrent or sequential adjuvant chemoradiotherapy after conservative surgery for early-stage breast cancer. Final clinical results of the ARCOSEIN phase III randomized trial. J Clin Oncol. 2007;25:405–410
  27. Burstein HJ, Bellon JR, Galper S, et al. Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer. Int J Radiat Oncol Biol Phys. 2006;64:496–504
  28. Taghian AG, Assaad SI, Niemierko A, et al. Risk of pneumonitis in breast cancer patients treated with radiation therapy and combination chemotherapy with paclitaxel. J Natl Cancer Inst. 2001;93:1806–1811
  29. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Trastuzumab in combination with docetaxel or vinorelbine as adjuvat treatment of breast cancer: the FinHer trial. N Engl J Med. 2006;354:809–820
  30. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2 positive breast cancer. N Engl J Med. 2005;353:1673–1684
  31. Piccart-Gebhart M, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy for HER2-positive breast cancer. N Engl J Med. 2005;353:1659–1672
  32. Benk V, Levinton C, Fortin PR, et al. Effect of delay in initiating radiotherapy for patients with early stage breast cancer: results of a natural experiment. Int J Radiat Oncol Biol Phys. 1999;45:305–306
  33. Mackillop WJ, Bates JHT, Withers HR. The effect of delay in treatment on local control by radiotherapy. Int J Radiat Oncol Biol Phys. 1996;34:243–250
  34. Tsoutsou P, Koukourakis MI, Azria D, Belkacemi Y. Optimal timing for adjuvant radiation therapy in breast cancer. A comprehensive review and perspectives. Crit Rev Oncol Hematol. 2009;71:102–116
  35. Buchholz T, Tucker S, Erwin J, et al. Impact of systemic treatment on local control for patients with lymph node-negative breast cancer treated with breast-conservation therapy. J Clin Oncol. 2001;19:2240–2246
  36. Truong PT, Bernstein V, Lesperance M, et al. Radiotherapy omission after breast-conserving surgery is associated with reduced breast cancer-specific survival in elderly women with breast cancer. Am J Surg. 2006;191:749–755
  37. Sanghani M, Balk E, Cady B, Wazer D. Predicting the risk of local recurrence in patients with breast cancer: an approach to a new computer-based predictive tool. Am J Clin Oncol. 2007;30:473–480
  38. Nguyen PL, Taghian AG, Katz MS, et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol. 2008;26:2373–2378
  39. Kyndi M, Sørensen FB, Knudsen H, et al. Danish Breast Cancer Cooperative Group. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol. 2008;26:1419–1426
  40. Haffty BG, Yang Q, Reiss M, et al. Loco-regional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol. 2006;24:5652–5657
  41. Parikh RR, Yang Q, Higgins SA, Haffty BG. Outcomes in young women with breast cancer of triple-negative phenotype: the prognostic significance of CK19 expression. Int J Radiat Oncol Biol Phys. 2008;70:35–42
  42. Belkacémi Y, Penault-Llorca F, Gligorov J, Azria D. The use of breast cancer subtype classification to predict local and distant recurrence. A review. Cancer Radiother. 2008;12:577–583
  43. Cutuli B, De Lafontan B, Vitali E, et al. Breast conserving treatment (BCT) for stage I–II breast cancer in elderly women: analysis of 927 cases. Crit Rev Oncol Hematol. 2009;71:79–88
  44. Kirova YM, Pena PC, Hijal T, et al. Improving the definition of tumor bed boost with the use of surgical clips and image registration in breast cancer patients. Int J Radiat Oncol Biol Phys. 2010;[Epub ahead of print]
  45. Dzhugashvili M, Pichenot C, Dunant A, et al. Surgical clips assist in the visualization of the lumpectomy cavity in three-dimensional conformal accelerated partial-breast irradiation. Int J Radiat Oncol Biol Phys. 2010;76:1320–1324
  46. Ceilley E, Jagsi R, Goldberg S, et al. Radiotherapy for invasive breast cancer in North America and Europe: results of a survey. Int J Radiat Oncol Biol Phys. 2005;61:365–373
  47. Recht A, Edge SB, Solin LJ, et al. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19:1539–1569
  48. Taghian AG, Jeong J-H, Mamounas EP, et al. Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5cm or larger treated by mastectomy, with or without systemic therapy and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized clinical trials. J Clin Oncol. 2006;24:3927–3932
  49. Taghian A, Jagsi R, Makris A, et al. Results of a survey regarding irradiation of internal mammary chain in patients with breast cancer: practice is culture driven rather than evidence based. Int J Radiat Oncol Biol Phys. 2004;60:706–714
  50. Huang O, Wang L, Shen K, et al. Breast cancer subpopulation with high risk of internal mammary lymph nodes metastasis: analysis of 2,269 Chinese breast cancer patients treated with extended radical mastectomy. Breast Cancer Res Treat. 2008;107:379–387
  51. Wazer DE, Di Petrillo T, Schmidt-Ullrich R, et al. Factors influencing cosmetic outcome and complication risk after conserving surgery and radiotherapy for early-stage breast carcinoma. J Clin Oncol. 1992;10:356–363
  52. Taylor ME, Perez CA, Halverson KJ, et al. Factors influencing cosmetic results after conservation therapy for breast cancer. Int J Radiat Oncol Biol Phys. 1995;31:753–764
  53. Fowble B, Fein DA, Hanlon AL, et al. The impact of tamoxifen on breast recurrence, cosmesis, complications, and survival in estrogen receptor-positive early-stage breast cancer. Int J Radiat Oncol Biol Phys. 1996;35:669–677
  54. Azria D, Gourgou S, Sozzi WJ, et al. Concomitant use of tamoxifen with radiotherapy enhances subcutaneous breast fibrosis in hypersensitive patients. Br J Cancer. 2004;91:1251–1260
  55. Bentzen SM, Skoczylas JZ, Overgaard M, et al. Radiotherapy-related lung fibrosis enhanced by tamoxifen. J Natl Cancer Inst. 1996;88:918–922
  56. Koc M, Polat P, Suma S. Effects of tamoxifen on pulmonary fibrosis after cobalt-60 radiotherapy in breast cancer patients. Radiother Oncol. 2002;64:171–175
  57. Kesisis G, Makris A, Miles D. Update on the use of aromatase inhibitors in early-stage breast cancer. Breast Cancer Res. 2009;11(5):211
  58. Recht A, Come SE, Gelman RS, et al. Integration of conservative surgery, radiotherapy, and chemotherapy for the treatment of early-stage, node-positive breast cancer: sequencing, timing, and outcome. J Clin Oncol. 1993;11:191–193
  59. Huang J, Barbera L, Brouwers M, et al. Does delay in starting treatment affect the outcomes of radiotherapy? A systematic review. J Clin Oncol. 2003;21:555–563
  60. Recht A, Come SE, Henderson IC, et al. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med. 1996;334:1356–1361
  61. Coates A. International Breast Cancer Study Group trials. Recent results. Cancer Res. 1998;152:429–440
  62. Belkacemi Y, Gligorov J, Ozsahin , et al. Adjuvant trastuzumab and radiation therapy in patients with HER2 breast cancer: a French multicenter prospective study. Ann Oncol. 2008;19:1110–1116
  63. Halyard MY, Pisansky TM, Dueck AC, et al. Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. J Clin Oncol. 2009;27:2638–2644
  64. Kirova YM, Caussa L, Granger B, et al. Monocentric evaluation of the skin and cardiac toxicities of the concomitant administration of trastuzumab and radiotherapy. Cancer Radiother. 2009;13:276–280
  65. Shaffer R, Tyldesley S, Rolles M, et al. Acute cardiotoxicity with concurrent trastuzumaband radiotherapy including internal mammary chain nodes: a retrospective single-institution study. Radiother Oncol. 2009;90:122–126
  66. Belkacemi Y, Gligorov J. Concurrent trastuzumab—Internal mammary irradiation for HER2 positive breast cancer: “It hurts to be on the cutting edge”. Radiother Oncol. 2009;
  67. Bellon JR, Gover MT, Burstein HJ, et al. Concurrent trastuzumab and radiation therapy (RT) in the adjuvant treatment of breast cancer. Proc. Int J Radiat Oncol Biol Phys. 2005;[Abstract 91]
  68. Harcourt DM, Rumsey NJ, Ambler NR, et al. The psychological effect of mastectomy with or without breast reconstruction: a prospective, multicenter study. Plast Reconstr Surg. 2003;111:1060–1068
  69. Cordeiro PG, Pusic AL, Disa JJ, et al. Irradiation after immediate tissue expander/implant breast reconstruction: outcomes, complications, aesthetic results, and satisfaction among 156 patients. Plast Reconstr Surg. 2004;113:877–881
  70. Jhaveri JD, Rush SC, Kostroff K, et al. Clinical outcomes of postmastectomy radiation therapy after immediate breast reconstruction. Int J Radiat Oncol Biol Phys. 2008;72:859–865
  71. Mehta VK, Goffinet D. Postmastectomy radiation therapy after TRAM flap breast reconstruction. Breast J. 2004;10:118–122
  72. Hebert-Croteau N, Freeman CR, Latreille J, et al. A population-based study of the impact of delaying radiotherapy after conservative surgery for breast cancer. Breast Cancer Res Treat. 2004;88:187–196
  73. Hershman DL, Wang X, McBride R, et al. Delay in initiating adjuvant radiotherapy following breast conservation surgery and its impact on survival. Int J Radiat Oncol Biol Phys. 2006;65(5):1353–1360
  74. Mikeljevic JS, Haward R, Johnston C, et al. Trends in postoperative radiotherapy delay and the effect on survival in breast cancer patients treated with conservation surgery. Br J Cancer. 2004;90:1343–1348
  75. Guidelines, minimal requirements and standard of cancer care around the Mediterranean Area: Report from the Collaborative Update ref by : AROME (Association of Radiotherapy and Oncology of the Mediterranean Area) working parties. AROME. Crit Rev Oncol Hematol. 2010 Apr 15. [Epub ahead of print].

PII: S1040-8428(10)00142-3

doi: 10.1016/j.critrevonc.2010.06.002

Critical Reviews in Oncology / Hematology
Volume 79, Issue 2 , Pages 91-102 , August 2011

Article Tools